The Lancet Oncology (LANCET ONCOL)

Publisher: Elsevier

Journal description

The Lancet Oncology is a monthly, review journal, with articles, viewpoints, news and reviews in oncology.

Current impact factor: 24.73

Impact Factor Rankings

2015 Impact Factor Available summer 2015
2013 / 2014 Impact Factor 24.725
2012 Impact Factor 25.117
2011 Impact Factor 22.589
2010 Impact Factor 17.764
2009 Impact Factor 14.47
2008 Impact Factor 13.283
2007 Impact Factor 12.247
2006 Impact Factor 10.119
2005 Impact Factor 7.855
2004 Impact Factor 7.47
2003 Impact Factor 6.83

Impact factor over time

Impact factor

Additional details

5-year impact 21.86
Cited half-life 3.70
Immediacy index 6.54
Eigenfactor 0.08
Article influence 8.54
Website Lancet Oncology, The website
Other titles The lancet oncology, Oncology
ISSN 1470-2045
OCLC 45075773
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details


  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • On author's personal website or institutional website
    • Publisher copyright and source must be acknowledged
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • RCUK and Wellcome Trust funded authors may deposit in any repository after 6 months embargo or immediately via Sponsored Articles
    • Other funding agencies may have an embargo period of 6 to 12 months
    • This policy is an exception to the default policies of 'Elsevier'
  • Classification
    ​ blue

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The management of intracranial germ cell tumours (ICGCT) is complex. It was agreed at the 2013 Third International ICGCT Symposium (Cambridge, UK) to undertake a multi-disciplinary Delphi process to identify consensus in their management. Seventy-seven delegates from the Symposium were selected as suitable experts and were invited to participate in the Delphi survey; 64 (83%) responded. Those invited represented multiple disciplines from the Far East, Australasia, Europe and America. Thirty-eight consensus statements, encompassing aspects of work-up, staging, treatment and follow-up, were prepared. To achieve consensus, statements required ≥70% agreement from ≥60% of respondents. Overall, 34/38 statements (89%) met consensus criteria. This international Delphi approach has defined key areas of consensus which will guide and streamline future management of ICGCT. In addition, it has identified areas of different understanding and practice internationally which should be the focus of future collaborative studies. Such efforts will likely translate into improved patient outcomes.
    The Lancet Oncology 12/2015;
  • [Show abstract] [Hide abstract]
    ABSTRACT: The optimum duration of androgen deprivation combined with high-dose radiotherapy in prostate cancer remains undefined. We aimed to determine whether long-term androgen deprivation was superior to short-term androgen deprivation when combined with high-dose radiotherapy. In this open-label, multicentre, phase 3 randomised controlled trial, patients were recruited from ten university hospitals throughout Spain. Eligible patients had clinical stage T1c-T3b N0M0 prostate adenocarcinoma with intermediate-risk and high-risk factors according to 2005 National Comprehensive Cancer Network criteria. Patients were randomly assigned (1:1) using a computer-generated randomisation schedule to receive either 4 months of androgen deprivation combined with three-dimensional conformal radiotherapy at a minimum dose of 76 Gy (range 76-82 Gy; short-term androgen deprivation group) or the same treatment followed by 24 months of adjuvant androgen deprivation (long-term androgen deprivation group), stratified by prostate cancer risk group (intermediate risk vs high risk) and participating centre. Patients assigned to the short-term androgen deprivation group received 4 months of neoadjuvant and concomitant androgen deprivation with subcutaneous goserelin (2 months before and 2 months combined with high-dose radiotherapy). Anti-androgen therapy (flutamide 750 mg per day or bicalutamide 50 mg per day) was added during the first 2 months of treatment. Patients assigned to long-term suppression continued with the same luteinising hormone-releasing hormone analogue every 3 months for another 24 months. The primary endpoint was biochemical disease-free survival. Analysis was by intention to treat. This study is registered with, number NCT02175212. Between Nov 7, 2005, and Dec 20, 2010, 178 patients were randomly assigned to receive short-term androgen deprivation and 177 to receive long-term androgen deprivation. After a median follow-up of 63 months (IQR 50-82), 5-year biochemical disease-free survival was significantly better among patients receiving long-term androgen deprivation than among those receiving short-term treatment (90% [95% CI 87-92] vs 81% [78-85]; hazard ratio [HR] 1·88 [95% CI 1·12-3·15]; p=0·01). 5-year overall survival (95% [95% CI 93-97] vs 86% [83-89]; HR 2·48 [95% CI 1·31-4·68]; p=0·009) and 5-year metastasis-free survival (94% [95% CI 92-96] vs 83% [80-86]; HR 2·31 [95% CI 1·23-3·85]; p=0·01) were also significantly better in the long-term androgen deprivation group than in the short-term androgen deprivation group. The effect of long-term androgen deprivation on biochemical disease-free survival, metastasis-free survival, and overall survival was more evident in patients with high-risk disease than in those with low-risk disease. Grade 3 late rectal toxicity was noted in three (2%) of 177 patients in the long-term androgen deprivation group and two (1%) of 178 in the short-term androgen deprivation group; grade 3-4 late urinary toxicity was noted in five (3%) patients in each group. No deaths related to treatment were reported. Compared with short-term androgen deprivation, 2 years of adjuvant androgen deprivation combined with high-dose radiotherapy improved biochemical control and overall survival in patients with prostate cancer, particularly those with high-risk disease, with no increase in late radiation toxicity. Longer follow-up is needed to determine whether men with intermediate-risk disease benefit from more than 4 months of androgen deprivation. Spanish National Health Investigation Fund, AstraZeneca. Copyright © 2015 Elsevier Ltd. All rights reserved.
    The Lancet Oncology 02/2015; DOI:10.1016/S1470-2045(15)70045-8.
  • The Lancet Oncology 12/2014; DOI:10.1016/S1470-2045(14)70401-2
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70477-2
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)71022-8
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70478-4
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70494-2
  • Source
    The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70370-5
  • Article: Cancer Hair
    The Lancet Oncology 11/2014; 15(12):1302. DOI:10.1016/S1470-2045(14)71098-8
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70479-6
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70497-8
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70492-9
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70493-0
  • The Lancet Oncology 11/2014; 15(12). DOI:10.1016/S1470-2045(14)70264-5